ReviewAAPS PharmSciTech2025
Progress and Prospects of Transdermal Treatment of Allergic Skin Diseases with Natural Drugs based on Nanotechnology.
Review in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Engineering pectin- and sodium alginate-based nanoemulgels for topical delivery ofRSC advances · 2026Article
- Nanotechnologies for Skin Drug Delivery: Polymeric, Bio-Based, and Hybrid Nanocarriers with Clinical and Translational Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Self-Assembled Nanoparticles of Licorice Extract Enhance Skin Penetration and Regulate Barrier Proteins via a Dual-Channel Pathway.Pharmaceutics · 2026Article
- Engineering Multi-Scale Transdermal Delivery Systems for Atopic Dermatitis: Emerging Insights from the Gut-Skin Axis.International journal of nanomedicine · 2026Review
- Nanomaterials in Targeted Immunotherapy for Chronic Spontaneous Urticaria: Focusing on Immune Cell Modulation and Precision Treatment.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic skin disease conditions represent a significant global health challenge, with conventional therapies frequently associated with local dermal irritation and systemic adverse effects. Nanotechnology-enabled transdermal drug delivery platforms present innovative approaches for the targeted and efficient administration of natural drugs. This paper presents an overview of the application of nanocarriers, including polymeric nanoparticles, lipid-based nanocarriers, and inorganic nanostructures, for managing allergic skin diseases by enhancing the solubility of natural drugs, improving transdermal permeation, and facilitating site-specific targeting. The synergistic integration of microneedle arrays and hydrogel matrices for sustained release and precise delivery is also analyzed. Furthermore, the potential of stimuli-responsive smart delivery systems to modulate the lesion microenvironment is explored. In future advancements, integrating artificial intelligence into the rational design of nanocarriers, developing 3D skin organoid models, and establishing dynamic efficacy assessment systems can expedite the clinical translation of novel nanomedicines. This approach offers a robust theoretical foundation and technical support for personalized therapy in allergic skin disease conditions.
Indexed as
Identifiers
41199004What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.